Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.

Q2 Medicine The Journal of rheumatology. Supplement Pub Date : 2021-06-01 DOI:10.3899/jrheum.201667

Carmel Stober, Deepak R Jadon, April W Armstrong, Vinod Chandran, Maarten de Wit, Philip S Helliwell, Philip J Mease, Alexis Ogdie, Denis O'Sullivan, Stephen R Pennington, Thorvardur Löve, Alberto Cauli, Leonieke van Mens, Robin Waxman, Jose U Scher, Anne Barton, Christopher T Ritchlin, Oliver FitzGerald

{"title":"Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.","authors":"Carmel Stober, Deepak R Jadon, April W Armstrong, Vinod Chandran, Maarten de Wit, Philip S Helliwell, Philip J Mease, Alexis Ogdie, Denis O'Sullivan, Stephen R Pennington, Thorvardur Löve, Alberto Cauli, Leonieke van Mens, Robin Waxman, Jose U Scher, Anne Barton, Christopher T Ritchlin, Oliver FitzGerald","doi":"10.3899/jrheum.201667","DOIUrl":null,"url":null,"abstract":"<p><p>At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a pilot investigator-initiated study protocol to test electronic case report forms (eCRFs) and proposed Standardized Operating Procedures (SOPs) to evaluate biomarkers of psoriatic arthritis (PsA) associated with axial disease. The progress on 3 studies was also presented: BioDAM PsA (Biomarkers as Predictors of structural DAMage in PsA; to validate soluble biomarkers as predictors of structural damage in PsA), PreventPsA (examining the development of PsA and risk factors among patients with psoriasis and no arthritis), and PredictORPsA (Predicting Treatment respOnse in patients with eaRly PsA; in collaboration with Pfizer using samples from the Oral Psoriatic Arthritis TriaL [OPAL], to identify biomarkers of treatment response). GRAPPA-CRN funding partnerships and applications are also underway with both the Innovative Medicines Initiative (IMI) in Europe and Accelerating Medicines Partnerships (AMP) 2.0 in the USA, and the progress of these applications and associated objectives were presented.</p>","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of rheumatology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.201667","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a pilot investigator-initiated study protocol to test electronic case report forms (eCRFs) and proposed Standardized Operating Procedures (SOPs) to evaluate biomarkers of psoriatic arthritis (PsA) associated with axial disease. The progress on 3 studies was also presented: BioDAM PsA (Biomarkers as Predictors of structural DAMage in PsA; to validate soluble biomarkers as predictors of structural damage in PsA), PreventPsA (examining the development of PsA and risk factors among patients with psoriasis and no arthritis), and PredictORPsA (Predicting Treatment respOnse in patients with eaRly PsA; in collaboration with Pfizer using samples from the Oral Psoriatic Arthritis TriaL [OPAL], to identify biomarkers of treatment response). GRAPPA-CRN funding partnerships and applications are also underway with both the Innovative Medicines Initiative (IMI) in Europe and Accelerating Medicines Partnerships (AMP) 2.0 in the USA, and the progress of these applications and associated objectives were presented.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2020年GRAPPA合作研究网络(CRN)会议纪要。

在2020年银屑病和银屑病关节炎研究与评估小组(GRAPPA)-合作研究网络(CRN)年会上，GRAPPA-CRN小组提出了一项试点研究者发起的研究方案，以测试电子病例报告表格(ecrf)和拟议的标准化操作程序(sop)，以评估与轴向疾病相关的银屑病关节炎(PsA)的生物标志物。介绍了3项研究进展:生物标志物作为PsA结构损伤的预测因子;验证可溶性生物标志物作为PsA结构损伤的预测因子)，PreventPsA(检查银屑病和无关节炎患者中PsA的发展和危险因素)和PredictORPsA(预测早期PsA患者的治疗反应;与辉瑞公司合作，使用口服银屑病关节炎试验(Oral Psoriatic Arthritis TriaL, OPAL)的样本，以确定治疗反应的生物标志物。欧洲的创新药物倡议(IMI)和美国的加速药物伙伴关系(AMP) 2.0也正在与GRAPPA-CRN资助伙伴关系和应用进行合作，并介绍了这些应用的进展和相关目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

The Journal of rheumatology. Supplement Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.